Last reviewed · How we verify
NCT05495386
Investigation of Hyposafe H02 Device in Patients With Type 1 Diabetes
NA trial testing Hyposafe hypoglycaemia notification device (H02) in Type 1 Diabetes. Withdrawn.
1 January 2024
Quick facts
| Lead sponsor | UNEEG Medical A/S |
|---|---|
| Phase | NA |
| Status | Withdrawn |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | other |
| Start date | 1 September 2022 |
| Primary completion | 1 January 2024 |
| Estimated completion | 1 March 2024 |
Drugs / interventions tested
- Hyposafe hypoglycaemia notification device (H02)
Conditions studied
- Type 1 Diabetes — all drugs for Type 1 Diabetes →
Sponsor
UNEEG Medical A/S
Who can join
Adults 18 to 70, any sex, with Type 1 Diabetes. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This clinical study is designed to collect data for further development of a hypoglycaemia notification algorithm. In addition, information regarding safety will be collected and analysed.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT05495386
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Type 1 Diabetes
Currently open trials in the same condition.
- NCT07061574 — A Randomized Phase 1/2 Trial of Low Dose Anti-thymocyte Globulin (ATG) With Subsequent Adalimumab or Verapamil in New On · Phase 1, PHASE2 · recruiting
- NCT07360080 — Long-Term Outcomes of Teplizumab in Routine Clinical Care · recruiting
- NCT07457580 — Real-World Study of Patients With Type 1 Diabetes Treated With Teplizumab as Part of Managed Access Programs (MAPs) · recruiting
- NCT07212179 — Safety and Feasibility of a Self-Learning Bolus Calculator With Simplified Meal Announcement in Adolescents With Type 1 · NA · recruiting
- NCT07287943 — To Study the Efficacy and Safety of Medtronic 780G Insulin Pump in People With Gastroparesis and Type 1 Diabetes. · NA · recruiting
Other UNEEG Medical A/S trials
Trials by the same sponsor.
- NCT06934005 — Safety and Performance of Short- and Long-term Baseplates for Attaching the UNEEG Episight Recorder - Part II · NA · completed
- NCT05111847 — Safety and Performance of Short- and Long-term Baseplates for Attaching the UNEEG Episight Recorder - Part I · NA · completed
- NCT04526418 — Evaluation of the 24/7 EEG SubQ System for Ultra Long-Term Recording of Patients With Epilepsy Involving the Temporal Lo · NA · terminated
- NCT04513743 — Ultra Long-Term Sleep Monitoring Using UNEEG™ Medical 24/7 EEG™ SubQ · NA · completed
- NCT02925676 — Evaluation of the Hypoglycaemia Notification Device Hyposafe H02 · NA · terminated
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05495386 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by UNEEG Medical A/S
- Last refreshed: 22 December 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05495386.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing